Table of Contents
Hepatitis Research and Treatment
Volume 2016, Article ID 7629318, 8 pages
http://dx.doi.org/10.1155/2016/7629318
Review Article

Atherosclerosis as Extrahepatic Manifestation of Chronic Infection with Hepatitis C Virus

4th Department of Internal Medicine, “Evangelismos” General Hospital, 45-47 Ipsilantou Street, 106 76 Athens, Greece

Received 11 October 2015; Accepted 20 December 2015

Academic Editor: Man-Fung Yuen

Copyright © 2016 Theodoros Voulgaris and Vassilios A. Sevastianos. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Lavanchy, “Evolving epidemiology of hepatitis C virus,” Clinical Microbiology and Infection, vol. 17, no. 2, pp. 107–115, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. F. Negro, D. Forton, A. Craxì, M. S. Sulkowski, J. J. Feld, and M. P. Manns, “Extrahepatic morbidity and mortality of chronic hepatitis C,” Gastroenterology, vol. 149, no. 6, pp. 1345–1360, 2015. View at Publisher · View at Google Scholar
  3. P. M. Jacobson Brown and M. G. Neuman, “Immunopathogenesis of hepatitis C viral infection: Th1/Th2 responses and the role of cytokines,” Clinical Biochemistry, vol. 34, no. 3, pp. 167–171, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. Z. Abbas and T. Moatter, “Interleukin (IL) 1beta and IL-10 gene polymorphism in chronic hepatitis C patients with normal or elevated alanine aminotransferase levels,” The Journal of the Pakistan Medical Association, vol. 53, no. 2, pp. 59–62, 2003. View at Google Scholar · View at Scopus
  5. L. E. Adinolfi, R. Zampino, L. Restivo et al., “Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms,” World Journal of Gastroenterology, vol. 20, no. 13, pp. 3410–3417, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Petta, D. Torres, G. Fazio et al., “Carotid atherosclerosis and chronic hepatitis C: a prospective study of risk associations,” Hepatology, vol. 55, no. 5, pp. 1317–1323, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Boddi, R. Abbate, B. Chellini et al., “Hepatitis C virus RNA localization in human carotid plaques,” Journal of Clinical Virology, vol. 47, no. 1, pp. 72–75, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. R. Moucari, T. Asselah, D. Cazals-Hatem et al., “Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis,” Gastroenterology, vol. 134, no. 2, pp. 416–423, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. J. M. Hui, A. Sud, G. C. Farrell et al., “Insulin resistance is associated with chronic hepatitis C and virus infection fibrosis progression,” Gastroenterology, vol. 125, no. 6, pp. 1695–1704, 2003. View at Publisher · View at Google Scholar
  10. C.-S. Wang, S.-T. Wang, W.-J. Yao, T.-T. Chang, and P. Chou, “Hepatitis C virus infection and the development of type 2 diabetes in a community-based longitudinal study,” American Journal of Epidemiology, vol. 166, no. 2, pp. 196–203, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. M. W. Douglas and J. George, “Molecular mechanisms of insulin resistance in chronic hepatitis C,” World Journal of Gastroenterology, vol. 15, no. 35, pp. 4356–4364, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. E. Bugianesi, F. Salamone, and F. Negro, “The interaction of metabolic factors with HCV infection: does it matter?” Journal of Hepatology, vol. 56, supplement 1, pp. S56–S65, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. G. Pasterkamp, “Methods of accelerated atherosclerosis in diabetic patients,” Heart, vol. 99, no. 10, pp. 743–749, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. N. Ishizaka, Y. Ishizaka, E. Takahashi et al., “Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening,” The Lancet, vol. 359, no. 9301, pp. 133–135, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. H. Tomiyama, T. Arai, K.-I. Hirose, S. Hori, Y. Yamamoto, and A. Yamashina, “Hepatitis C virus seropositivity, but not hepatitis B virus carrier or seropositivity, associated with increased pulse wave velocity,” Atherosclerosis, vol. 166, no. 2, pp. 401–403, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Mostafa, M. K. Mohamed, M. Saeed et al., “Hepatitis C infection and clearance: impact on atherosclerosis and cardiometabolic risk factors,” Gut, vol. 59, no. 8, pp. 1135–1140, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. L. E. Adinolfi, L. Restivo, R. Zampino et al., “Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis,” Atherosclerosis, vol. 221, no. 2, pp. 496–502, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. H. Huang, R. Kang, and Z. Zhao, “Hepatitis C virus infection and risk of stroke: a systematic review and meta-analysis,” PLoS ONE, vol. 8, no. 11, Article ID e81305, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Masia, S. Padilla, C. Robledano, J. M. Ramos, and F. Gutierrez, “Evaluation of endothelial function and subclinical atherosclerosis in association with hepatitis C virus in HIV-infected patients: a cross-sectional study,” BMC Infectious Diseases, vol. 11, article 265, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. Y. Caliskan, H. Oflaz, H. Püsüroglu et al., “Hepatitis C virus infection in hemodialysis patients is not associated with insulin resistance, inflammation and atherosclerosis,” Clinical Nephrology, vol. 71, no. 2, pp. 147–157, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. P. C. Tien, M. F. Schneider, S. R. Cole et al., “Association of hepatitis C virus and HIV infection with subclinical atherosclerosis in the women's interagency HIV study,” AIDS, vol. 23, no. 13, pp. 1781–1784, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. H. Völzke, C. Schwahn, B. Wolff et al., “Hepatitis B and C virus infection and the risk of atherosclerosis in a general population,” Atherosclerosis, vol. 174, no. 1, pp. 99–103, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. C. Vassalle, S. Masini, F. Bianchi, and G. C. Zucchelli, “Evidence for association between hepatitis C virus seropositivity and coronary artery disease,” Heart, vol. 90, no. 5, pp. 565–566, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. A. A. Butt, W. Xiaoqiang, M. Budoff, D. Leaf, L. H. Kuller, and A. C. Justice, “Hepatitis C virus infection and the risk of coronary disease,” Clinical Infectious Diseases, vol. 49, no. 2, pp. 225–232, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. O. Alyan, F. Kacmaz, O. Ozdemir et al., “Hepatitis C infection is associated with increased coronary artery atherosclerosis defined by modified reardon severity score system,” Circulation Journal, vol. 72, no. 12, pp. 1960–1965, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. L. E. Adinolfi, L. Restivo, B. Guerrera et al., “Chronic HCV infection is a risk factor of ischemic stroke,” Atherosclerosis, vol. 231, no. 1, pp. 22–26, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. C. P. M. S. Oliveira, C. R. Kappel, E. R. Siqueira et al., “Effects of hepatitis C virus on cardiovascular risk in infected patients: a comparative study,” International Journal of Cardiology, vol. 164, no. 2, pp. 221–226, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. C. Enger, U. M. Forssen, D. Bennett, D. Theodore, S. Shantakumar, and A. McAfee, “Thromboembolic events among patients with hepatitis C virus infection and cirrhosis: a matched-cohort study,” Advances in Therapy, vol. 31, no. 8, pp. 891–903, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. S. K. Satapathy, Y. J. Kim, A. Kataria et al., “Higher prevalence and more severe coronary artery disease in hepatitis C virus-infected patients: a case control study,” Journal of Clinical and Experimental Hepatology, vol. 3, no. 3, pp. 186–191, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. N. V. K. C. Pothineni, R. Delongchamp, S. Vallurupalli et al., “Impact of hepatitis C seropositivity on the risk of coronary heart disease events,” American Journal of Cardiology, vol. 114, no. 12, pp. 1841–1845, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. R. J. Wong, F. Kanwal, Z. M. Younossi, and A. Ahmed, “Hepatitis C virus infection and coronary artery disease risk: a systematic review of the literature,” Digestive Diseases and Sciences, vol. 59, no. 7, pp. 1586–1593, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. K. A. Forde, K. Haynes, A. B. Troxel et al., “Risk of myocardial infarction associated with chronic hepatitis C virus infection: a population-based cohort study,” Journal of Viral Hepatitis, vol. 19, no. 4, pp. 271–277, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. C. M. Arcari, K. E. Nelson, D. M. Netski, F. J. Nieto, and C. A. Gaydos, “No association between hepatitis C virus seropositivity and acute myocardial infarction,” Clinical Infectious Diseases, vol. 43, no. 6, pp. e53–e56, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. Y. Momiyama, R. Ohmori, R. Kato, H. Taniguchi, H. Nakamura, and F. Ohsuzu, “Lack of any association between persistent hepatitis B or C virus infection and coronary artery disease,” Atherosclerosis, vol. 181, no. 1, pp. 211–213, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Lonardo, L. E. Adinolfi, P. Loria, N. Carulli, G. Ruggiero, and C. P. Day, “Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease,” Gastroenterology, vol. 126, no. 2, pp. 586–597, 2004. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Fargion, M. Porzio, and A. L. Fracanzani, “Nonalcoholic fatty liver disease and vascular disease: state-of-the-art,” World Journal of Gastroenterology, vol. 20, no. 37, pp. 13306–13324, 2014. View at Publisher · View at Google Scholar · View at Scopus
  37. G. Targher, L. Bertolini, R. Padovani, S. Rodella, G. Arcaro, and C. Day, “Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis B and C,” Journal of Hepatology, vol. 46, no. 6, pp. 1126–1132, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. Y. Ishizaka, N. Ishizaka, E. Takahashi et al., “Association between hepatitis C virus core protein and carotid atherosclerosis,” Circulation Journal, vol. 67, no. 1, pp. 26–30, 2003. View at Publisher · View at Google Scholar · View at Scopus
  39. L. E. Adinolfi, L. Restivo, and A. Marrone, “The predictive value of steatosis in hepatitis C virus infection,” Expert Review of Gastroenterology and Hepatology, vol. 7, no. 3, pp. 205–213, 2013. View at Publisher · View at Google Scholar · View at Scopus
  40. H. Huang, R. Kang, and Z. Zhao, “Is hepatitis C associated with atherosclerotic burden? A systematic review and meta-analysis,” PLoS ONE, vol. 9, no. 9, Article ID e106376, 2014. View at Publisher · View at Google Scholar · View at Scopus
  41. U. Forssen, A. McAfee, C. Enger, D. Bennett, and S. Shantakumar, “Risk of thromboembolic events (TEs) among patients infected with hepatitis C,” Hepatology, vol. 50, article 672A, 2009. View at Google Scholar
  42. C.-C. Liao, T.-C. Su, F.-C. Sung, W.-H. Chou, and T.-L. Chen, “Does hepatitis C virus infection increase risk for stroke? A population-based cohort study,” PLoS ONE, vol. 7, no. 2, Article ID e31527, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. M.-H. Lee, H.-I. Yang, S.-N. Lu et al., “Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study,” Journal of Infectious Diseases, vol. 206, no. 4, pp. 469–477, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. C.-S. Hsu, J.-H. Kao, Y.-C. Chao et al., “Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients: a population-based cohort study in Taiwan,” Alimentary Pharmacology & Therapeutics, vol. 38, no. 4, pp. 415–423, 2013. View at Publisher · View at Google Scholar · View at Scopus
  45. Z. M. Younossi, M. Stepanova, F. Nader, Z. Younossi, and E. Elsheikh, “Associations of chronic hepatitis C with metabolic and cardiac outcomes,” Alimentary Pharmacology and Therapeutics, vol. 37, no. 6, pp. 647–652, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. U. Vespasiani-Gentilucci, P. Gallo, A. De Vincentis, G. Galati, and A. Picardi, “Hepatitis C virus and metabolic disorder interactions towards liver damage and atherosclerosis,” World Journal of Gastroenterology, vol. 20, no. 11, pp. 2825–2838, 2014. View at Publisher · View at Google Scholar · View at Scopus
  47. E. L. Ellis and D. A. Mann, “Clinical evidence for the regression of liver fibrosis,” Journal of Hepatology, vol. 56, no. 5, pp. 1171–1180, 2012. View at Publisher · View at Google Scholar · View at Scopus
  48. S. L. George, B. R. Bacon, E. M. Brunt, K. L. Mihindukulasuriya, J. Hoffman, and A. M. Di Bisceglie, “Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients,” Hepatology, vol. 49, no. 3, pp. 729–738, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. V. Mallet, H. Gilgenkrantz, J. Serpaggi et al., “Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C,” Annals of Internal Medicine, vol. 149, no. 6, pp. 399–403, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. H. Yoshida, R. Tateishi, Y. Arakawa et al., “Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C,” Gut, vol. 53, no. 3, pp. 425–430, 2004. View at Publisher · View at Google Scholar · View at Scopus
  51. S. Bruno, T. Stroffolini, M. Colombo et al., “Sustained virological response to interferon-α is associated with improved outcome in HCV-related cirrhosis: a retrospective study,” Hepatology, vol. 45, no. 3, pp. 579–587, 2007. View at Publisher · View at Google Scholar · View at Scopus
  52. K. W. Chew, L. Hua, D. Bhattacharya et al., “The effect of hepatitis C virologic clearance on cardiovascular disease biomarkers in human immunodeficiency virus/hepatitis C virus coinfection,” Open Forum Infectious Diseases, vol. 1, no. 3, Article ID ofu104, 2014. View at Publisher · View at Google Scholar
  53. M. A. Khattab, M. Eslam, M. Shatat et al., “Changes in adipocytokines and insulin sensitivity during and after antiviral therapy for hepatitis C genotype 4,” Journal of Gastrointestinal and Liver Diseases, vol. 21, no. 1, pp. 59–65, 2012. View at Google Scholar · View at Scopus